QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Halozyme Therapeutics, Inc. (HALO) Announces Completion of Enrollment of Phase III Study 0 comments
    Dec 8, 2010 5:26 PM | about stocks: HALO

    Biopharmaceutical company Halozyme Therapeutics, Inc. announced today that Roche has completed patient enrollment for the pivotal Phase III study of Herceptin SC. The compound is a subcutaneous formulation that uses Halozyme’s Enhanze technology.

    The Phase III trial is a randomized, open-label, non-inferiority design that has enrolled 595 patients with early stage HER2-positive breast cancer. The study will evaluate two primary endpoints that compare Herceptin administered IV and SC for complete pathologic response between treatment cycles 8 and 9 and serum concentration during the first 8 cycles. Secondary endpoints will also be measured in this investigational study including an evaluation of safety and tolerability.

    In the study, patients will receive chemotherapy concurrent with either Herceptin intravenous (IV) or Herceptin SC every three weeks for the first 8 cycles. Halozyme’s subcutaneous alternative is expected to take less than five minutes to administer and should allow patients with HER2-positive breast cancer to receive their treatment in their physician’s office or potentially at home without having to go to a hospital.

    Gregory Frost, Ph.D., Halozyme’s president and CEO, commented, “The timely completion of patient enrollment for this multicenter Phase III clinical trial marks a significant achievement for the Herceptin SC development program and exemplifies the full support and commitment of the Halozyme-Roche alliance to offering patients more advanced treatment options. Herceptin SC has the potential to offer both patient benefits and treatment efficiencies, and I congratulate the team on this important accomplishment.”

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Stocks: HALO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.